The IRIS Program: A Novel Pathway to Optimize Treatment of Injection-related Infections for People Who Inject Drugs in Hamilton, Ontario
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- McMaster University
- Enrollment
- 80
- Locations
- 4
- Primary Endpoint
- Number of emergency department visits and hospital readmission
Study Overview
Brief Summary
People who inject drugs are at risk of injection-related infections, like abscesses or infective endocarditis. The Injection-Related InfectionS (IRIS) program hopes to improve treatment for participants by providing a low-barrier, one-stop shop model for people who inject drugs who experience injection-related infections to access more holistic and compassionate care. IRIS is a non-randomized clinical trial, meaning that it offers a specific program to eligible patients. This program offers care for substance use and infectious disease with additional peer support and systems navigation, if interested. The investigators anticipate enrolling 80 participants in the intervention and will follow participants throughout the infection treatment period (estimated 6-12 weeks). The investigators will collect information at the time of enrolment, at the 6-month mark, and monthly via electronic medical chart review. The investigators will use an interrupted time series analysis to evaluate the impact of the intervention on rates of treatment completion, emergency department visits, hospitalizations, and death, before versus after the intervention.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 16 Years to 105 Years (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age 16 or older
- •Able to provide informed consent
- •Presenting with a confirmed or suspected injection-related infection (including skin and soft tissue infections, osteomyelitis, infective endocarditis, Hepatitis C, HIV, etc)
- •History of injection drug use within 3 months of recruitment
- •Lives in Hamilton, Ontario
Exclusion Criteria
- Not provided
Arms & Interventions
Intervention group
Participants in the IRIS program will be offered a one-stop, low-barrier combined care model to address their injection-related infections. Specific program components include: (1) Diagnosis and treatment of injection-related infections; (2) Substance use treatment (3) Peer support; and (4) Care coordination/systems navigation.
Intervention: Holistic injection-related injection treatment (Other)
Outcomes
Primary Outcomes
Number of emergency department visits and hospital readmission
Time Frame: Within 30 days of initial hospital admission or program enrolment
Secondary Outcomes
- Number of hospital readmissions specifically for the infection that was the primary reason for program enrolment(Within 90-days of hospital discharge or program enrolment)
- Number of emergency department visits(Within 90-days of hospital discharge or program enrolment)
- Rates of program drop-out and reasons for discontinuation(Within 6-months of hospital discharge or program enrolment)
- Completion of intended course of treatment for the injection-related infection(Within 6 months of initial hospital admission or program enrolment)
- Number of new initiations or record of continuation of substance use treatment(Within 90-days of hospital discharge or program enrolment)
- Mortality rates(Within 6-months of hospital discharge or program enrolment)